Drug Profile
ABT 767
Alternative Names: ABT-767Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Netherlands (PO)
- 30 Nov 2017 ABT 767 is still in phase I trials for Solid tumours (Late-stage disease, Metastatic disease) in Netherlands (PO) (NCT01339650)
- 30 Nov 2017 AbbVie completes a phase-I trial in Solid tumours (Late-stage disease, Metastatic disease) in Netherlands (PO) (NCT01339650)